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Biased agonism, the ability of a receptor to differentially activate downstream signaling
pathways depending on binding of a “biased” agonist compared to a “balanced” agonist,
is a well-established paradigm for G protein-coupled receptor (GPCR) signaling. Biased
agonists have the promise to act as smarter drugs by specifically targeting pathogenic
or therapeutic signaling pathways while avoiding others that could lead to side effects.
A number of biased agonists targeting a wide array of GPCRs have been described,
primarily based on their signaling in pharmacological assays. However, with the promise
of biased agonists as novel therapeutics, comes the peril of not fully characterizing and
understanding the activities of these compounds. Indeed, it is likely that some of the
compounds that have been described as biased, may not be if quantitative approaches
for bias assessment are used. Moreover, cell specific effects can result in “system
bias” that cannot be accounted by current approaches for quantifying ligand bias.
Other confounding includes kinetic effects which can alter apparent bias and differential
propagation of biological signal that results in different levels of amplification of reporters
downstream of the same effector. Moreover, the effects of biased agonists frequently
cannot be predicted from their pharmacological profiles, and must be tested in the
vivo physiological context. Thus, the development of biased agonists as drugs requires
a detailed pharmacological characterization, involving both qualitative and quantitative
approaches, and a detailed physiological characterization. With this understanding, we
stand on the edge of a new era of smarter drugs that target GPCRs.
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INTRODUCTION
G protein-coupled receptors (GPCRs) are the most common receptors in the genome and one
of the largest drug targets for neuroendocrine disease (Overington et al., 2006). Classically, drugs
targeting these receptors have been considered along the spectrum from antagonists to partial
agonists to full agonists, which block, partially activate or fully activate, respectively, all of the
signaling pathways downstream of a receptor. Over the past two decades, we have now appreciated
a different phenomenon, biased agonism (in contrast to “balanced agonism”), the ability of some
ligands to selectively activate some signaling pathways while blocking others (Rajagopal et al.,
2010). Biased agonism was first noted as a reversal of the order of potencies for different ligands
between alternative G protein signaling pathways (Kenakin, 1995). While the study of biased
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agonism has largely focused on GPCRs, it is likely to occur
in other receptor types as well (Zheng et al., 2012). A biased
response is due to a combination of two distinct phenomena,
ligand bias and system bias (Kenakin and Christopoulos, 2013b).
Ligand bias, or “true” biased agonism, refers to differences
in signaling due to the molecular variation that governs the
interaction between the ligand and the transduction proteins at
the receptor. Ligand bias is thought to be due to the stabilization
of distinct receptor conformational states that differentially
activate these alternative signaling pathways (Kahsai et al., 2011;
Liu et al., 2012; Wacker et al., 2013). For GPCRs, the easiest bias
to observe is that between selective activation of heterotrimeric G
proteins (G protein-bias) and β-arrestin (β-arrestin-bias) adapter
proteins (Wei et al., 2003). This is because G proteins and β-
arrestins typically activate distinct signaling pathways, with G
proteins typically activating second messengers and β-arrestins
regulating receptor desensitization, internalization and activation
of MAP kinases (DeWire et al., 2007). In contrast, system bias,
or “apparent” biased agonism, is a reflection of the differences in
measurements of biochemical amplification at the tissue, cellular,
or in vitro level between the assays that are being used (Onaran
and Costa, 2012). Thus, system bias has contributions from true
differential amplification of signaling pathways (amplification
bias) and the assays used to assess these signaling pathways
(observation bias). In the development of biased agonists, it is
critical to apply approaches that can separate ligand bias, which
should be present across different assays, from system bias.
Biased agonists are expected to have different functional
and physiological consequences from conventional balanced
agonists, given that they activate only a select portion of a
receptor’s signaling cascade while inhibiting others (Whalen
et al., 2011). Because so many drugs target GPCRs, biased
agonism holds the promise of developing a whole new class of
“smarter” drugs that selectively target therapeutically relevant
signaling pathway with fewer side effects from non-selective
activation or blockade of other signaling pathways. A few
therapeutics in the clinic have since been shown to act as biased
agonists, whichmay explain why some drugs have greater efficacy
than others within the same class (Kim et al., 2008). Conversely,
failure to account for the potential of biased agonism may
lead to the development of pharmaceuticals that may target the
relevant signaling pathway while, at the same time, activating
pathways leading to intolerable side effects. The goal of this
perspective is to highlight examples of drug development of
biased agonists, current limitations in their characterization and
a general approach to characterizing the pharmacology of this
promising new class of drugs.
THE PROMISE OF BIASED AGONISM
For biased agonists to be developed as drugs, a clear
understanding of their physiological effects must be determined.
Biased agonists targeting a number of disease states have been
and are currently being developed (reviewed in Whalen et al.,
2011; Kenakin and Christopoulos, 2013b), and a review of all
of those studies is beyond the scope of this perspective. Rather,
we will focus on biased drug development at two receptors
that are important in the nervous system: The dopamine D2
receptor and the µ-opioid receptor (µOR). Dopamine D2
receptors were originally thought to affect schizophrenia through
Gαi/Gα0-mediated inhibition of adenylyl cyclase (Girault and
Greengard, 2004). Based on that understanding, one would
expect that blockade of G protein-mediated D2 signaling would
be sufficient to treat schizophrenia. However, behavioral and
biochemical evidence has since shown a central role of β-arrestin
2 in signal transduction by D2 dopamine receptors through the
regulation of the AKT-GSK3 pathway (Beaulieu et al., 2007),
through the formation of a protein complex composed of β-
arrestin 2, AKT, and PP2A that promotes the dephosphorylation
of AKT in response to dopamine. Lithium, a common drug
used to treat bipolar disorder and other psychiatric illnesses,
targets this protein complex, as do a wide array of antipsychotic
medications (Masri et al., 2008). In β-arrestin 2 knockout mice,
the behavioral effects of lithium treatment are lost, and the mice
display defects in behaviors known to be regulated by dopamine
(Beaulieu et al., 2008). More recently, a β-arrestin-biased D2
receptor agonist has been developed (Allen et al., 2011) that
has distinct effects from balanced agonists in a mouse model of
schizophrenia (Park et al., 2016).
The µOR is the target for endogenous enkephalin peptides
and exogenous opioid analgesics including morphine, which act
as agonists. Enkephalins are balanced agonists for G protein-
and β-arrestin-mediated pathways, whereas morphine is biased
toward G protein-mediated signaling, with a considerable
reduction of receptor phosphorylation and internalization
(Bohn et al., 2004). However, β-arrestin 2 knockout mice
have demonstrated amplified and prolonged morphine-
induced analgesia compared to wild type mice, consistent
with the presence of morphine-induced β-arrestin-mediated
desensitization (Bohn et al., 1999). Furthermore, β-arrestin 2
knockout mice are protected from the side effects of morphine
such as respiratory depression and constipation, which suggests
that β-arrestin-mediated pathways control these peripheral
side effects (Bohn et al., 2000). Recently, G protein-biased
µOR agonists have been developed using different strategies
(DeWire et al., 2013; Manglik et al., 2016). These drugs provide
analgesia in animal models without the side effects of respiratory
depression and tolerance (DeWire et al., 2013; Manglik et al.,
2016), and one of these compounds has already shown promise
in early phase clinical trials in humans (Soergel et al., 2014).
LIMITATIONS TO IDENTIFYING BIASED
AGONISTS
While there is considerable promise in the development of biased
agonists as therapeutics, there are a number of considerations
that must be addressed when characterizing a biased agonist,
from the pharmacological to the physiological levels (Table 1).
Make Sure Your Ligand is Actually Biased
Many older studies assumed that a ligand was biased compared
to a balanced agonist if there was a significant difference in
efficacies or potencies through different signaling pathways.
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TABLE 1 | Limitations to the assessment of biased agonism and
approaches to minimize them.
Problem Solution
Ensure that the ligand
is biased
• Choose assays to minimize difference in amplification
• Use qualitative and quantitative approaches for
assessing ligand bias and removing effects of system
bias
Confounding by
cell-specific effects
• Use cells that are as close to physiological as possible
• Validate findings from heterologous system in more
physiologically relevant cell type
Unexpected
propagation of bias
• Obtain data from multiple time points to ensure that
bias persists over biologically relevant time scale
• Assess different reporters downstream of the same
effector to ensure similar degrees of bias
Complex/Unexpected
physiology
• Test effects of biased agonists in physiologically
relevant cell types and animal models of disease
However, large differences in potency and efficacy can be due
to system bias and not ligand bias (Onaran and Costa, 2012).
One of the first methods for properly identifying biased ligands
was by identifying a change in the rank order of potency of
ligands (Kenakin, 1995). Over the past few years, a number
of approaches have been developed to identify and quantify
ligand bias through the calculation of “bias factors” (reviewed
in Kenakin and Christopoulos, 2013a). While a full discussion
of the details of these different approaches is beyond the scope
of this perspective, we discuss some of their advantages and
disadvantages below (see General Approach).
Avoid Confounding by Cell-Specific Effects
Even with our current approaches for assessing bias, it is
still possible that the effects of system bias cannot be fully
accounted for. For example, the bias factor approaches based
on the operational model are best suited for cases in which the
major difference is a change in receptor number or immediate
downstream amplification, as the τ factor (an estimate of efficacy)
is equal to receptor concentration divided by a constant for
system amplification (Black and Leff, 1983). The operational
model cannot correct for examples in which other cofactors
that affect signaling, such as GRKs, are differentially expressed.
For example, GRK2 overexpression is known to phosphorylate
the µOR and increase β-arrestin recruitment to the receptor in
response to morphine (Zhang et al., 1998). However, a recent
study has shown that GRK2 activity at the µOR generates a
unique conformation of the receptor that is associated with
differential activity (Nickolls et al., 2013). This type of behavior
cannot be accounted for using pharmacological methods for
quantifying bias.
Watch for Unexpected Propagation of Bias
A recent study by Klein Herenbrink et al. (2016) highlighted
that apparent bias may change depending on the time and
pathway assessed. At the D2 dopamine receptor, they found that
there was a significant effect of ligand-binding kinetics and the
temporal pattern of receptor-signaling processes on the observed
bias of different ligands. These differences even led to some
examples of reversals in the direction of bias. Most methods
for determining bias factors assume equilibrium conditions, a
situation which is clearly absent when there is a significant
kinetic effect. Also, the authors found that different reporters of
the same pathway could have different degrees of amplification
and estimated bias. At the µOR, a robust correlation was
found between off-rate kinetics for ligands and slower receptor
dephosphorylation and β-arrestin dissocation (Sianati, 2014),
suggesting similar behaviors at other GPCRs. These kinetic effects
must be considered in the assessment of bias.
Characterize the Physiological Effects of
the Biased Agonist
It is common for the pharmacological effects of a drug to
not correspond with its in vivo activity, due to off-target
effects or unexpected biology. This is especially true for biased
agonists, which have more complex effects than simple agonists
or antagonists. For example, SII angiotensin is a synthetically
modified form of angiotensin II that binds the angiotensin type
1A receptor (AT1AR) (Holloway et al., 2002). SII is unable
to activate Gαq signaling but retains the ability to recruit
β-arrestin 2, which would be expected to result a loss of
calcium signaling with increased desensitization (Wei et al.,
2004). However, SII was found to act as a calcium sensitizer in
cardiomyocytes (Rajagopal et al., 2006; Monasky et al., 2013)
through a novel β-arrestin regulatory mechanism. Subsequent
work, however, has shown that the signaling pattern induced
by SII is much more complex, and involves activation of other
G protein-dependent effects, suggesting that the relationship
between observed bias and physiological effects is more complex
(Sauliere et al., 2012). Thus, sometimes it can be difficult
to establish a clear connectivity between biased coupling and
cellular behavior. For example, at the urotensin receptor, ligands
which differentially activated Gq, G13, Gi/o,and β-arrestin, do not
display clear patterns for their effects on cell death, migration
and adhesion (Brule et al., 2014). It is critical to characterize
signaling pathways activated by biased agonists in physiologically
relevant tissues, as these can be very different from heterologously
expressed cells.
A GENERAL APPROACH TO IDENTIFYING
AND CHARACTERIZING BIASED
AGONISTS
Based on these considerations, we recommend the following
approach to identify biased agonists (Figure 1A). First, to
limit possible cell-specific effects, cells that are as close to
physiologically relevant as possible should be used for the
assays used to test bias. This can be difficult, however, as
most physiologically relevant cell lines are difficult to transfect
and not suited to most pharmacological assays. Therefore,
it is important to confirm, after a potential biased agonist
has been identified, that its biochemical effects are observed
in a physiological relevant cell type. Second, in choosing
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FIGURE 1 | General approach to assessing biased agonism. (A) Considerations for assay development in characterizing biased agonists. (B) Bias plots are
generated by converting dose-response data for 2 signaling pathways (G protein and β-arrestin signaling here) to response 1 vs. response 2 data (here β-arrestin vs. G
protein signaling). If there is significant amplification between assays, the window for identifying G protein-biased ligands decreases significantly (top panel). To identify
both G protein- and β-arrestin-biased, assays with similar levels of amplification should be used (bottom panel). (C) Approaches to quantifying bias based on the
presence of binding data (dissociation constant, KD ) and whether the concentration-response data is best fit with a Hill coefficient (n) of non-unity. All of these
approaches can yield a bias factor, β. For more details on these different approaches, please refer to the text.
the assays for different signaling pathways, they should have
similar levels of amplification, i.e., these assays should generate
similar signals for the same concentration of ligand (Rajagopal
et al., 2010). This provides a larger window for identifying
biased agonists (Figure 1B). For example, assays that measure
second messengers downstream of G proteins, such as cyclic
AMP (cAMP) or calcium, have significant amplification.
This is in contrast to recruitment assays of G proteins or
β-arrestins to the receptor using bioluminescence resonance
energy transfer (BRET), in which the spatial proximity of a
luciferase (RLuc) -tagged receptor to a yellow fluorescent protein
(YFP)-tagged effector results in energy transfer. In a BRET
assay, the YFP:Rluc ratio indicates the degree of recruitment,
with virtually no amplification. Assays that report on receptor
internalization can be useful in determining receptor distribution
in response to ligand stimulation, as shortly after β-arrestin
recruitment, receptors undergo endocytosis and rapid or slow
recycling. Using reporters that are significantly distal to the
receptor runs the risk that they may report on other effectors,
e.g., MAP kinase activation is regulated both by G proteins and
β-arrestins. Third, to avoid confounding from potential kinetic
effects, it is important to collect time-dependent data to ensure
that any bias persists across a valid biological time scale. Lastly,
the effects of biased agonists should be tested in cellular and
animal models, as little may be known about the physiological
effects of a biased agonist.
With respect to the specific methods used to quantify ligand
bias, both qualitative and quantitative methods should be used
to identify potentially biased ligands (Rajagopal et al., 2011).
Most quantative approaches for bias result in the calculation of a
“bias factor” that quantifies the degree of ligand bias numerically.
The details of bias factor calculations are beyond the scope of
this perspective, and the interested reader should refer to the
specific citations below. First, use “bias plots” to qualitatively
identify potentially biased ligands (Figure 1B) (Gregory et al.,
2010). If a ligand does not demonstrate bias on the bias plot
(has a similar response-response curve on the bias plot to the
balanced agonist) but does have a significant bias factor, it is
likely that the bias factor calculation is in error. This is because
errors in a bias factor can be introduced at multiple stages
in the fitting of concentration-response data depending on the
technique used. If the data is fit well with a simple dose-response
equation with a Hill coefficient of 1, the most straightforward
approach to calculate a bias factor is by the logarithm of ratios
of relative intrinsic activities (Griffin et al., 2007; Rajagopal et al.,
2011) (Figure 1C). This calculation does not require additional
information on ligand binding nor a complex fitting routine (it
just requires Emaxs and EC50s for the different assays) that could
introduce errors into the bias factor. An alternative approach
is to calculate transduction coefficients (Kenakin et al., 2012),
although that should be mathematically identical with bias
factors obtained from intrinsic relative activities when the Hill
coefficient is 1 (Griffin et al., 2007).
If binding data for ligands and a reference agonist are
available, fitting to an operational model (Black and Leff, 1983)
can yield both bias factors and estimates of efficacy. This
estimate of efficacy (the effective signaling, σ) (Rajagopal et al.,
2011), is closely related to intrinsic efficacy, ε, from classic
pharmacological theory (Onaran et al., 2014). The advantage
of this estimate of efficacy is that it provides information to
the degree of agonism of the ligand tested, e.g., whether the
ligand is a weak partial agonist or a full agonist. This data is
not provided by a bias factor, which only gives an estimate of
the relative efficacies of two signaling pathways compared to
one another for a single ligand. As an example, a bias factor
cannot differentiate between a weak partial agonist that is biased
and a similarly biased full agonist; comparing their effective
signaling can differentiate between such drugs. This approach
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should provide efficacy estimates even if the Hill coefficient is
not unity.
If binding data is not unavailable and the Hill coefficient is
not one, then the best approach to use is the calculation of
transduction coefficients (Kenakin et al., 2012). In this approach,
transduction coefficients [log(τ/KA)] are fit to the data along
with an “apparent” dissociation constant; bias factors can be
calculated from these transduction coefficients. For a partial
agonist, in which the Emax for the ligand does not approach
the maximal effect of the system, the EC50 approaches the
dissociation constant for the ligand, KD. In that situation, the
data will be well fit with the transduction coefficient equation.
However, for full agonists, where Emax approaches the maximal
effect of the system, there may not be a clear relationship between
EC50 and KD. This can result in an ambiguous fit associated with
relatively larger errors for estimates in transduction coefficients
and bias factors.
CONCLUSIONS
Drug discovery of biased agonists is an active area of research
which has exploded over the past 5 years. In the development
of biased agonists, it is critical that potential limitations
in their characterization should be minimized. This means
that we must confirm that the ligand is actually biased
using qualitative and quantitative approaches, that there is no
significant confounding from cell-specific effects, that there is not
unexpected propagation or kinetic effects in signaling and that
we understand the physiological effects of the biased agonists
in cellular and animal models of disease. Using this general
approach, a broad understanding of signaling by biased agonists
from the pharmacological to the physiological level can be
obtained and we can move forward in the development of these
promising agents as novel therapeutics.
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